vs
Side-by-side financial comparison of PHIBRO ANIMAL HEALTH CORP (PAHC) and Qfin Holdings, Inc. (QFIN). Click either name above to swap in a different company.
Qfin Holdings, Inc. is the larger business by last-quarter revenue ($731.2M vs $373.9M, roughly 2.0× PHIBRO ANIMAL HEALTH CORP). Qfin Holdings, Inc. runs the higher net margin — 27.5% vs 7.3%, a 20.2% gap on every dollar of revenue. Over the past eight quarters, PHIBRO ANIMAL HEALTH CORP's revenue compounded faster (19.2% CAGR vs 16.4%).
Phibro Animal Health Corporation is an American animal health and mineral nutrition company. Its products include antibacterials, anticoccidials, anthelmintics, as well as animal nutrition and vaccines for livestock. The company operates through three segments Mineral Nutrition, Performance Materials, and Animal Health, from which most of its revenue is derived. The company operates in the United States, Latin America, Canada, Europe, Middle East, Africa, and Asia-Pacific. It is incorporated ...
Qfin Holdings Inc. is a leading China-based fintech enterprise that mainly provides intelligent credit solutions, risk management technology support, and digital financial service tools. It collaborates with licensed financial institutions to serve individual consumers and micro, small and medium-sized enterprises across China, using big data and artificial intelligence to boost financial inclusion and operational efficiency.
PAHC vs QFIN — Head-to-Head
Income Statement — Q2 FY2026 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $373.9M | $731.2M |
| Net Profit | $27.5M | $201.2M |
| Gross Margin | 35.5% | — |
| Operating Margin | 13.5% | 32.7% |
| Net Margin | 7.3% | 27.5% |
| Revenue YoY | 20.9% | — |
| Net Profit YoY | 762.1% | — |
| EPS (diluted) | $0.67 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $373.9M | — | ||
| Q3 25 | $363.9M | $731.2M | ||
| Q2 25 | $378.7M | $728.1M | ||
| Q1 25 | $347.8M | $646.4M | ||
| Q4 24 | $309.3M | — | ||
| Q3 24 | $260.4M | $622.7M | ||
| Q2 24 | $273.2M | $572.4M | ||
| Q1 24 | $263.2M | $575.2M |
| Q4 25 | $27.5M | — | ||
| Q3 25 | $26.5M | $201.2M | ||
| Q2 25 | $17.2M | $241.6M | ||
| Q1 25 | $20.9M | $247.6M | ||
| Q4 24 | $3.2M | — | ||
| Q3 24 | $7.0M | $256.3M | ||
| Q2 24 | $752.0K | $189.4M | ||
| Q1 24 | $8.4M | $160.7M |
| Q4 25 | 35.5% | — | ||
| Q3 25 | 32.9% | — | ||
| Q2 25 | 29.0% | — | ||
| Q1 25 | 30.1% | — | ||
| Q4 24 | 32.9% | — | ||
| Q3 24 | 32.1% | — | ||
| Q2 24 | 31.9% | — | ||
| Q1 24 | 30.2% | — |
| Q4 25 | 13.5% | — | ||
| Q3 25 | 14.1% | 32.7% | ||
| Q2 25 | 8.9% | 41.0% | ||
| Q1 25 | 9.6% | 42.1% | ||
| Q4 24 | 8.3% | — | ||
| Q3 24 | 6.8% | 52.4% | ||
| Q2 24 | 6.7% | 47.7% | ||
| Q1 24 | 7.6% | 32.8% |
| Q4 25 | 7.3% | — | ||
| Q3 25 | 7.3% | 27.5% | ||
| Q2 25 | 4.5% | 33.2% | ||
| Q1 25 | 6.0% | 38.3% | ||
| Q4 24 | 1.0% | — | ||
| Q3 24 | 2.7% | 41.2% | ||
| Q2 24 | 0.3% | 33.1% | ||
| Q1 24 | 3.2% | 27.9% |
| Q4 25 | $0.67 | — | ||
| Q3 25 | $0.65 | — | ||
| Q2 25 | $0.43 | — | ||
| Q1 25 | $0.51 | — | ||
| Q4 24 | $0.08 | — | ||
| Q3 24 | $0.17 | — | ||
| Q2 24 | $0.02 | — | ||
| Q1 24 | $0.21 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $74.5M | $6.5B |
| Total DebtLower is stronger | $624.2M | — |
| Stockholders' EquityBook value | $332.4M | $24.3B |
| Total Assets | $1.4B | $61.4B |
| Debt / EquityLower = less leverage | 1.88× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $74.5M | — | ||
| Q3 25 | $85.3M | $6.5B | ||
| Q2 25 | $77.0M | $5.3B | ||
| Q1 25 | $70.4M | $8.6B | ||
| Q4 24 | $67.1M | — | ||
| Q3 24 | $89.8M | $4.3B | ||
| Q2 24 | $114.6M | $6.3B | ||
| Q1 24 | $98.7M | $5.3B |
| Q4 25 | $624.2M | — | ||
| Q3 25 | $628.0M | — | ||
| Q2 25 | $631.7M | — | ||
| Q1 25 | $635.4M | — | ||
| Q4 24 | $639.1M | — | ||
| Q3 24 | $295.2M | — | ||
| Q2 24 | $312.1M | — | ||
| Q1 24 | — | — |
| Q4 25 | $332.4M | — | ||
| Q3 25 | $311.7M | $24.3B | ||
| Q2 25 | $285.7M | $24.1B | ||
| Q1 25 | $266.0M | $23.1B | ||
| Q4 24 | $246.8M | — | ||
| Q3 24 | $258.5M | $22.9B | ||
| Q2 24 | $256.6M | $22.6B | ||
| Q1 24 | $270.1M | $22.1B |
| Q4 25 | $1.4B | — | ||
| Q3 25 | $1.4B | $61.4B | ||
| Q2 25 | $1.4B | $59.8B | ||
| Q1 25 | $1.3B | $55.6B | ||
| Q4 24 | $1.3B | — | ||
| Q3 24 | $966.3M | $47.0B | ||
| Q2 24 | $982.2M | $47.0B | ||
| Q1 24 | $979.0M | $47.4B |
| Q4 25 | 1.88× | — | ||
| Q3 25 | 2.01× | — | ||
| Q2 25 | 2.21× | — | ||
| Q1 25 | 2.39× | — | ||
| Q4 24 | 2.59× | — | ||
| Q3 24 | 1.14× | — | ||
| Q2 24 | 1.22× | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $19.4M | $351.4M |
| Free Cash FlowOCF − Capex | $8.3M | — |
| FCF MarginFCF / Revenue | 2.2% | — |
| Capex IntensityCapex / Revenue | 3.0% | — |
| Cash ConversionOCF / Net Profit | 0.70× | 1.75× |
| TTM Free Cash FlowTrailing 4 quarters | $47.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $19.4M | — | ||
| Q3 25 | $9.3M | $351.4M | ||
| Q2 25 | $21.3M | $366.0M | ||
| Q1 25 | $43.2M | $386.6M | ||
| Q4 24 | $3.1M | — | ||
| Q3 24 | $12.6M | $338.0M | ||
| Q2 24 | $28.4M | $269.9M | ||
| Q1 24 | $11.4M | $271.2M |
| Q4 25 | $8.3M | — | ||
| Q3 25 | $-4.5M | — | ||
| Q2 25 | $8.1M | — | ||
| Q1 25 | $35.4M | — | ||
| Q4 24 | $-4.7M | — | ||
| Q3 24 | $3.0M | — | ||
| Q2 24 | $15.4M | — | ||
| Q1 24 | $1.7M | — |
| Q4 25 | 2.2% | — | ||
| Q3 25 | -1.2% | — | ||
| Q2 25 | 2.1% | — | ||
| Q1 25 | 10.2% | — | ||
| Q4 24 | -1.5% | — | ||
| Q3 24 | 1.2% | — | ||
| Q2 24 | 5.6% | — | ||
| Q1 24 | 0.6% | — |
| Q4 25 | 3.0% | — | ||
| Q3 25 | 3.8% | — | ||
| Q2 25 | 3.5% | — | ||
| Q1 25 | 2.2% | — | ||
| Q4 24 | 2.5% | — | ||
| Q3 24 | 3.7% | — | ||
| Q2 24 | 4.8% | — | ||
| Q1 24 | 3.7% | — |
| Q4 25 | 0.70× | — | ||
| Q3 25 | 0.35× | 1.75× | ||
| Q2 25 | 1.24× | 1.52× | ||
| Q1 25 | 2.07× | 1.56× | ||
| Q4 24 | 0.97× | — | ||
| Q3 24 | 1.81× | 1.32× | ||
| Q2 24 | 37.80× | 1.43× | ||
| Q1 24 | 1.36× | 1.69× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PAHC
| Medicated Feed Additives And Others | $202.1M | 54% |
| Mineral Nutrition | $68.9M | 18% |
| Nutritional Specialties | $50.2M | 13% |
| Vaccines | $37.6M | 10% |
| Performance Products | $15.0M | 4% |
QFIN
Segment breakdown not available.
